Literature DB >> 12650766

The recombinant Omp31 from Brucella melitensis alone or associated with rough lipopolysaccharide induces protection against Brucella ovis infection in BALB/c mice.

Silvia M Estein1, Juliana Cassataro, Nieves Vizcaíno, Michel S Zygmunt, Axel Cloeckaert, Raúl A Bowden.   

Abstract

Immunogenicity and protective activity against Brucella ovis of detergent-extracted recombinant Omp31 (rOmp31 extract) from Brucella melitensis produced in Escherichia coli, purified rough lipopolysaccharide from B. ovis (R-LPS) and a mixture of rOmp31 extract and R-LPS (rOmp31 extract + R-LPS) were assessed in BALB/c mice. The experimental vaccines were compared with a hot saline extract (HS extract) from B. ovis mainly composed of outer membrane proteins (OMPs) and R-LPS, and known to be protective in mice against a B. ovis infection. Serum antibodies to Omp31 and R-LPS were detected in the corresponding mice using Western blotting with B. ovis whole-cell lysates and ELISA with purified antigens. Protection was evaluated by comparing the levels of infection in the spleens of vaccinated mice challenged with B. ovis. A significantly lower number of B. ovis colony-forming units in spleens relative to unimmunized (saline injected) controls were considered as protection. Mice immunized with rOmp31 extract or rOmp31 extract mixed with R-LPS developed antibodies that bound to the B. ovis surface with similar titers. Vaccination with rOmp31 extract plus R-LPS provided the best protection level, which was comparable with that given by HS extract. Similar protection was also obtained with rOmp31 extract alone and, to a lesser degree, with R-LPS. Comparisons between groups showed that an extract from E. coli-pUC19 (devoid of Omp31) provided no protection relative to either HS extract, rOmp31 extract or rOmp31 extract mixed with R-LPS. In conclusion, the recombinant Omp31 associated or not with B. ovis R-LPS, could be an interesting candidate for a subcellular vaccine against B. ovis infection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12650766     DOI: 10.1016/s1286-4579(02)00075-8

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  17 in total

1.  Characterization of new members of the group 3 outer membrane protein family of Brucella spp.

Authors:  Imed Salhi; Rose-Anne Boigegrain; Jan Machold; Christoph Weise; Axel Cloeckaert; Bruno Rouot
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

2.  Vaccination with the recombinant Brucella outer membrane protein 31 or a derived 27-amino-acid synthetic peptide elicits a CD4+ T helper 1 response that protects against Brucella melitensis infection.

Authors:  Juliana Cassataro; Silvia M Estein; Karina A Pasquevich; Carlos A Velikovsky; Silvia de la Barrera; Raúl Bowden; Carlos A Fossati; Guillermo H Giambartolomei
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

3.  A DNA vaccine coding for the Brucella outer membrane protein 31 confers protection against B. melitensis and B. ovis infection by eliciting a specific cytotoxic response.

Authors:  Juliana Cassataro; Carlos A Velikovsky; Silvia de la Barrera; Silvia M Estein; Laura Bruno; Raúl Bowden; Karina A Pasquevich; Carlos A Fossati; Guillermo H Giambartolomei
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

4.  Evaluation of the efficacy of outer membrane protein 31 vaccine formulations for protection against Brucella canis in BALB/c mice.

Authors:  Maria Clausse; Alejandra G Díaz; Andrés E Ibañez; Juliana Cassataro; Guillermo H Giambartolomei; Silvia M Estein
Journal:  Clin Vaccine Immunol       Date:  2014-10-22

5.  Invasive Escherichia coli vaccines expressing Brucella melitensis outer membrane proteins 31 or 16 or periplasmic protein BP26 confer protection in mice challenged with B. melitensis.

Authors:  V K Gupta; G Radhakrishnan; J Harms; G Splitter
Journal:  Vaccine       Date:  2012-04-28       Impact factor: 3.641

6.  Immunization with Brucella VirB proteins reduces organ colonization in mice through a Th1-type immune response and elicits a similar immune response in dogs.

Authors:  Cora N Pollak; María Magdalena Wanke; Silvia M Estein; M Victoria Delpino; Norma E Monachesi; Elida A Comercio; Carlos A Fossati; Pablo C Baldi
Journal:  Clin Vaccine Immunol       Date:  2014-12-24

7.  Partial protection against Brucella infection in mice by immunization with nonpathogenic alphaproteobacteria.

Authors:  M Victoria Delpino; Silvia M Estein; Carlos A Fossati; Pablo C Baldi
Journal:  Clin Vaccine Immunol       Date:  2007-08-22

8.  Sustained and differential antibody responses to virulence proteins of Brucella melitensis during acute and chronic infections in human brucellosis.

Authors:  J Xu; Y Qiu; M Cui; Y Ke; Q Zhen; X Yuan; Y Yu; X Du; J Yuan; H Song; Z Wang; G Gao; S Yu; Y Wang; L Huang; Z Chen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-11-15       Impact factor: 3.267

9.  Antibody reactivity to Omp31 from Brucella melitensis in human and animal infections by smooth and rough Brucellae.

Authors:  Juliana Cassataro; Karina Pasquevich; Laura Bruno; Jorge C Wallach; Carlos A Fossati; Pablo C Baldi
Journal:  Clin Diagn Lab Immunol       Date:  2004-01

10.  Improved immunogenicity of a vaccination regimen combining a DNA vaccine encoding Brucella melitensis outer membrane protein 31 (Omp31) and recombinant Omp31 boosting.

Authors:  Juliana Cassataro; Carlos A Velikovsky; Laura Bruno; Silvia M Estein; Silvia de la Barrera; Raúl Bowden; Carlos A Fossati; Guillermo H Giambartolomei
Journal:  Clin Vaccine Immunol       Date:  2007-04-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.